iSpecimen Inc.
Close on Oct 19, 2026
- Market cap
- $1.27M
- P/E (TTM)
- –
- Dividend yield
- –
About iSpecimen
Services-Commercial Physical & Biological Research, SIC 8731
iSpecimen Inc. operates an online marketplace platform that connects life science researchers with healthcare provider organizations supplying human biospecimens, including biofluids, tissues, and living cells, along with associated clinical data. The platform harmonizes de-identified patient and specimen data from electronic medical records, laboratory information systems, and biobank inventory systems into a centralized dataset. This system enables researchers to search for specific cohorts, request quotes, configure custom collections, and place orders. The company serves clients across industry, academia, and government institutions.
The company operates a global network of centralized healthcare supply partners. As of December 31, 2025, its marketplace platform had harmonized data covering approximately 19 million patient records, 105 million clinical specimen records, 1.4 million banked specimen records, and 1.2 million medical conditions. Since inception, the business has delivered more than 218,000 specimens across more than 3,500 projects. iSpecimen is headquartered in Woburn, Massachusetts.
Summary of the business section of iSpecimen's latest annual report, written by StockData.
Company profile
Company
- Legal name
- iSpecimen Inc.
- Headquarters
- Woburn, MA
- Address
- 8 Cabot Road, Suite 1800 08101
- Phone
- (781) 301-6700
- Employees
- 53, Dec 31, 2023
- Industry
- Services-Commercial Physical & Biological Research
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- Bush & Associates CPA LLC, Las Vegas, Nevada
Stock & identifiers
- Ticker
- ISPC
- Exchange
- Nasdaq
- IPO date
- Jun 21, 2021
- Shares outstanding
- 3M, Aug 14, 2026
- Public float
- $2.45M, Jun 30, 2025
- Filer category
- <br>Emerging growth company
- Stock splits
- 1-for-40 reverse, May 18, 2026; 1-for-40 reverse, Apr 28, 2026; 1-for-20 reverse, Oct 1, 2024; 1-for-20 reverse, Sep 16, 2024
- SEC CIK
- 1558569
- CUSIP
- 45032V306
- ISIN
- US45032V3069
- EIN
- 27-0480143
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Robert Bradley Lim | Chief Executive Officer, Director | – |
| Yuying Liang | Chief Financial Officer | – |
| Arphing Lee | Director | – |
Employees
Headcount reported in annual reports
“As of December 31, 2023, we had fifty-three employees (not including co-ops or summer interns), ten of whom were engaged in research and development activities, eleven of whom were engaged in sales and marketing activities, eighteen of whom were engaged in operations and fulfillment activities, five of whom were engaged in supply development and manag”
Corporate history
Events identified from SEC filings